Magainin gets project back
Genentech has terminated its licensing agreement with Magainin Pharmaceuticals covering the IL9 antibody development programme and related respiratory technology. Magainin says Genentech's decision does not reflect negatively on the science, and it will continue to develop the product, hopefully with another partner.